GEMCITABINE DRLA gemcitabine (as hydrochloride) 200 mg powder for injection vial

Negara: Australia

Bahasa: Inggris

Sumber: Department of Health (Therapeutic Goods Administration)

Bahan aktif:

gemcitabine hydrochloride, Quantity: 227.71 mg (Equivalent: gemcitabine, Qty 200 mg)

Tersedia dari:

Dr Reddys Laboratories Australia Pty Ltd

INN (Nama Internasional):

Gemcitabine hydrochloride

Bentuk farmasi:

Injection, powder for

Komposisi:

Excipient Ingredients: sodium acetate trihydrate; hydrochloric acid; sodium hydroxide; mannitol

Rute administrasi :

Intravenous

Unit dalam paket:

1 vial

Jenis Resep:

(S4) Prescription Only Medicine

Indikasi Terapi:

Gemcitabine DRLA is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,Gemcitabine DRLA is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ,Gemcitabine DRLA is also indicated for patients with 5-FU refractory pancreatic cancer. ,Gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,Gemcitabine DRLA in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,Gemcitabine DRLA in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Ringkasan produk:

Visual Identification: White to off white lyophilized powder; Container Type: Vial; Container Material: Glass; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status otorisasi:

Licence status A

Tanggal Otorisasi:

2013-07-23